id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
8949576_3 | We report a case of amiodarone-induced thyrotoxicosis of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[20]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19151423_3 | The addition of ciprofloxacin to chronic simvastatin therapy led to the development of rhabdomyolysis. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"led\"]], \"start\": [[61]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin\", \"chronic simvastatin\"]], \"start\": [[16, 33]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"chronic simvastatin\"]], \"start\": [[16], [33]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"addition\"]], \"start\": [[4]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"chronic simvastatin\"]], \"start\": [[16], [33]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[87]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
941054_1 | Nephropathy caused by methicillin therapy for staphylococcal septicemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Nephropathy\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methicillin therapy for staphylococcal septicemia\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"staphylococcal septicemia\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"methicillin\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
2028358_1 | Four patients in whom pulmonary oedema developed during tocolysis with hexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Four patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Four\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"pulmonary oedema\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"tocolysis with hexoprenaline\"]], \"start\": [[56]], \"entity_id\": [\"T1\"], \"Drug\": {\"text\": [[\"hexoprenaline\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
7379406_2 | A case of skeletal fluorosis induced by prolonged treatment with niflumic acid, a fast-acting non-steroid antiinflammatory agent, is reported in a 35-year-old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"niflumic acid\", \"in addition, with corticosteroids\"]], \"start\": [[65, 214]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"niflumic acid\"], [\"corticosteroids\"]], \"start\": [[65], [232]], \"entity_id\": [\"T16\", \"T17\"]}, \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[180]], \"entity_id\": [\"T19\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"addition\"]], \"start\": [[217]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"corticosteroids\"], [\"niflumic acid\"]], \"start\": [[232], [65]], \"entity_id\": [\"T17\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"skeletal fluorosis\"]], \"start\": [[10]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"a 35-year-old woman suffering from rheumatoid arthritis\"]], \"start\": [[145]], \"entity_id\": [\"T12\"], \"Age\": {\"text\": [[\"35-year-old\"]], \"start\": [[147]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[159]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
16637972_1 | A 65-year-old man on warfarin therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"a sudden spontaneous onset of sub-conjunctival haematoma associated with bloody tears\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A 65-year-old man\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"65-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"warfarin therapy\"]], \"start\": [[21]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"warfarin\"]], \"start\": [[21]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
11749112_2 | This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[31]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"tiagabine\"]], \"start\": [[155]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"bipolar disorder\"]], \"start\": [[117]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"tiagabine\"]], \"start\": [[155]], \"entity_id\": [\"T14\"]}}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[104]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"asymptomatic visual field defects\"]], \"start\": [[46]], \"entity_id\": [\"T13\"]}}"
}
]
}
] |
7436161_1 | Cardiorespiratory toxicity due to miconazole. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Cardiorespiratory toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"miconazole\"]], \"start\": [[34]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"miconazole\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9220046_5 | Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"clarithromycin\", \"azithromycin\", \"Lovastatin\"]], \"start\": [[59, 78, 0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"clarithromycin\"], [\"azithromycin\"], [\"Lovastatin\"]], \"start\": [[59], [78], [0]], \"entity_id\": [\"T8\", \"T9\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[74]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"clarithromycin\"], [\"azithromycin\"]], \"start\": [[59], [78]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"possibly\"]], \"start\": [[34]], \"entity_id\": [\"T12\"], \"value\": true}}"
}
]
}
] |
10490907_14 | For prevention of CYP2E1-mediated bioactivation, depending on protoxicant disposition, a second DSF dose might be necessary to completely prevent toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[124]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"a second DSF dose\"]], \"start\": [[87]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"protoxicant\"], [\"DSF\"]], \"start\": [[62], [96]], \"entity_id\": [\"T9\", \"T11\"]}, \"Dosage\": {\"text\": [[\"a second DSF dose\"]], \"start\": [[87]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
3438585_3 | We describe a patient with rheumatoid arthritis treated with gold salts, who developed bilateral interstitial pulmonary abnormalities and showed a dramatic response on corticosteroid therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated with\"]], \"start\": [[48]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"gold salts\"]], \"start\": [[61]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"gold salts\"], [\"corticosteroid\"]], \"start\": [[61], [168]], \"entity_id\": [\"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[27]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"bilateral interstitial pulmonary abnormalities\"]], \"start\": [[87]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a patient with rheumatoid arthritis\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
9184269_5 | Pneumonitis is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with MTX. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[111]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[116]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[116]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Pneumonitis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"potentially\"]], \"start\": [[61]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
8771575_1 | A chronic reaction associated with long-term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[102]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"long-term treatment with nitrofurantoin\"]], \"start\": [[35]], \"entity_id\": [\"T3\"], \"Dosage\": {\"text\": [[\"long-term treatment\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"nitrofurantoin\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"irreversible pulmonary fibrosis\"]], \"start\": [[109]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19789166_2 | Nitrofurantoin-induced acute liver damage in pregnancy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[15]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Nitrofurantoin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Nitrofurantoin\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute liver damage\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"pregnancy\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12656748_1 | A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia (CML) after continuous uneventful treatment with hydroxyurea for 18 yr. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"A 58-yr-old male patient with essential thrombocythaemia (ET)\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"58-yr-old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"chronic myeloid leukaemia (CML)\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"continuous uneventful treatment with hydroxyurea for 18 yr\"]], \"start\": [[110]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"essential thrombocythaemia (ET)\"]], \"start\": [[30]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"hydroxyurea\"]], \"start\": [[147]], \"entity_id\": [\"T12\"]}, \"Duration\": {\"text\": [[\"18 yr\"]], \"start\": [[163]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
7538828_2 | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate (MTX). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[89]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"skin rash and bone marrow aplasia\"]], \"start\": [[106]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"a single dose of 40 mg/m2 methotrexate (MTX)\"]], \"start\": [[178]], \"entity_id\": [\"T14\"], \"Disorder\": {\"text\": [[\"recurrent metastatic squamous cell carcinoma of the head and neck\"]], \"start\": [[23]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"40 mg/m2\"]], \"start\": [[195]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[204]], \"entity_id\": [\"T17\"]}, \"Freq\": {\"text\": [[\"a single dose\"]], \"start\": [[178]], \"entity_id\": [\"T19\"]}, \"Time_elapsed\": {\"text\": [[\"4 and 7 days\"]], \"start\": [[140]], \"entity_id\": [\"T18\"]}}, \"Subject\": {\"text\": [[\"A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck\"]], \"start\": [[0]], \"entity_id\": [\"T15\"], \"Age\": {\"text\": [[\"64 year old\"]], \"start\": [[2]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[14]], \"entity_id\": [\"T13\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[99]], \"entity_id\": [\"T20\"], \"value\": \"High\"}}"
}
]
}
] |
4004433_3 | We present four cases in which the use of heparin was associated with hyperkalemia and discuss the pathophysiology. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"four cases\"]], \"start\": [[11]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[11]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"heparin\"]], \"start\": [[42]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"heparin\"]], \"start\": [[42]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hyperkalemia\"]], \"start\": [[70]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16968538_6 | Three cycles of chemotherapy had been administered without complications when, at the beginning of the fourth cycle, the patient developed clinical and laboratory abnormalities consistent with the development of the hemolytic-uremic syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[129]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hemolytic-uremic syndrome.\"]], \"start\": [[216]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"chemotherapy\", \"at the beginning of the fourth cycle\"]], \"start\": [[16, 79]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"chemotherapy\"]], \"start\": [[16]], \"entity_id\": [\"T8\"]}, \"Duration\": {\"text\": [[\"fourth cycle\"]], \"start\": [[103]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[117]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
8862924_1 | Keratitis in methamphetamine abusers. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[10]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Keratitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"methamphetamine abusers\"]], \"start\": [[13]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methamphetamine\"]], \"start\": [[13]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9399776_3 | A rechallenge, performed in both patients, confirmed the diagnosis of mesalamine-induced pancreatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[81]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"mesalamine\"]], \"start\": [[70]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"mesalamine\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"pancreatitis\"]], \"start\": [[89]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"both patients\"]], \"start\": [[28]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8197046_1 | Central nervous system toxicity associated with meperidine use in hepatic disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Central nervous system toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"meperidine\"]], \"start\": [[48]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"hepatic disease\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"meperidine\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
12066972_2 | To our knowledge, this case is the first published report of levofloxacin-induced TEN. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[74]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"levofloxacin\"]], \"start\": [[61]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"levofloxacin\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"TEN\"]], \"start\": [[82]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
7282702_3 | On the second day of hospitalization, it was noted that the patient's dyspnea and sinus bradycardia could be related to a recent increase in his timolol dosage. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"dyspnea and sinus bradycardia\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"a recent increase in his timolol dosage\"]], \"start\": [[120]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"timolol\"]], \"start\": [[145]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"could\"]], \"start\": [[100]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
10870485_1 | Three months following splenectomy, multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"while\"]], \"start\": [[94]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"multiple abscesses occurred in the muscles of both thighs\"]], \"start\": [[36]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[100]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Three months following splenectomy\", \"third course of the CHOP regimen\"]], \"start\": [[0, 130]], \"entity_id\": [\"T5\"], \"Duration\": {\"text\": [[\"Three months\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"splenectomy\"], [\"CHOP\"]], \"start\": [[23], [150]], \"entity_id\": [\"T8\", \"T10\"]}, \"Dosage\": {\"text\": [[\"third course\"]], \"start\": [[130]], \"entity_id\": [\"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[116]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"CHOP\"], [\"splenectomy\"]], \"start\": [[150], [23]], \"entity_id\": [\"T10\", \"T8\"]}}]}}"
}
]
}
] |
19423610_9 | Methylene blue is used in a variety of surgical settings as well as for treatment of various types of hypotensive shock and methemoglobinaemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Methylene blue\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"hypotensive shock\"], [\"methemoglobinaemia\"]], \"start\": [[102], [124]], \"entity_id\": [\"T8\", \"T9\"]}, \"Drug\": {\"text\": [[\"Methylene blue\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9554064_1 | Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"central nervous system insult\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Methanol toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"Methanol\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[28]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
11737689_5 | We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G-CSF therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[97]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"skin eruptions\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"G-CSF\"]], \"start\": [[122]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"G-CSF\"]], \"start\": [[122]], \"entity_id\": [\"T9\"]}}, \"Speculated\": {\"text\": [[\"believe\"]], \"start\": [[3]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
3892171_4 | Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first fatal case of type I anaphylaxis resulting from protamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[152]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"protamine\"]], \"start\": [[167]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"protamine\"]], \"start\": [[167]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"fatal case of type I anaphylaxis\"]], \"start\": [[119]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[119]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
2595431_4 | We have reported six cases of metoclopramide-induced parkinsonism seen in consultation over a two-year period. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"six cases\"]], \"start\": [[17]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"six\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"metoclopramide\"]], \"start\": [[30]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"metoclopramide\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"parkinsonism\"]], \"start\": [[53]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
14514135_1 | Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient: a complication of cyclophosphamide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[87]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[103]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"lupus\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"cyclophosphamide\"]], \"start\": [[103]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"Neutrophilic eccrine hidradenitis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a lupus patient\"]], \"start\": [[68]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
10656221_1 | Gliclazide-induced acute hepatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Gliclazide\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Gliclazide\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"acute hepatitis\"]], \"start\": [[19]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8435665_1 | A 16-year-old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan, which were given during his initial induction chemotherapy and also after autologous marrow transplantation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[58]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A 16-year-old white male with acute biphenotypic leukemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"16-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T7\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"acute biphenotypic leukemia\"]], \"start\": [[30]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"eosinophilia myalgia syndrome\"]], \"start\": [[84]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"total parenteral nutritional support with solutions containing tryptophan, which were given during his initial induction chemotherapy and also after autologous marrow transplantation\"]], \"start\": [[130]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"tryptophan\"]], \"start\": [[193]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"parenteral\"]], \"start\": [[136]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
16268429_2 | Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related to\"]], \"start\": [[38]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Subacute cholestatic hepatitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"use of senna\"]], \"start\": [[53]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"senna\"]], \"start\": [[60]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"chronic constipation.\"]], \"start\": [[70]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
12460237_2 | Palmar-plantar erythrodysaesthesia (PPE) is an uncommon cutaneous complication of cytotoxic chemotherapy which generally presents as a painful erythema involving the palms and soles. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Palmar-plantar erythrodysaesthesia (PPE)\", \"an uncommon cutaneous complication\", \"a painful erythema involving the palms and soles\"]], \"start\": [[0, 44, 133]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"cytotoxic chemotherapy\"]], \"start\": [[82]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cytotoxic\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"chemotherapy\"]], \"start\": [[92]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
19363904_2 | We report a case of an 11-year-old boy who experienced an anaphylactic reaction after administration of bacitracin ointment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experienced\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an 11-year-old boy\"]], \"start\": [[20]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"11-year-old\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[35]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"an anaphylactic reaction\"]], \"start\": [[55]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"after administration of bacitracin ointment\"]], \"start\": [[80]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bacitracin\"]], \"start\": [[104]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
15661067_2 | The patient was found to have no motile sperm with a normal sperm count, while taking a dose of 400 mg/day of carbamazepine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"found\"]], \"start\": [[16]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"The patient\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"no motile sperm with a normal sperm count\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"400 mg/day of carbamazepine\"]], \"start\": [[96]], \"entity_id\": [\"T5\"], \"Dosage\": {\"text\": [[\"400 mg/day\"]], \"start\": [[96]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[110]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
990658_2 | A fatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and lithium carbonate. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"A fatal pancytopenia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a patient with an history of depression with hypomanic rebounds\"]], \"start\": [[33]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"depression\"], [\"hypomanic rebounds\"]], \"start\": [[62], [78]], \"entity_id\": [\"T10\", \"T12\"]}}, \"Treatment\": {\"text\": [[\"treated with levomepromazine, diazepam and lithium carbonate\"]], \"start\": [[131]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"a manic episode\"]], \"start\": [[111]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"levomepromazine\"], [\"diazepam\"], [\"lithium carbonate\"]], \"start\": [[144], [161], [174]], \"entity_id\": [\"T13\", \"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[170]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"levomepromazine\"], [\"diazepam\"], [\"lithium carbonate\"]], \"start\": [[144], [161], [174]], \"entity_id\": [\"T13\", \"T15\", \"T16\"]}}]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[2]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |
15133245_2 | Oxatomide is an antiallergic drug used for the treatment of diseases mediated by type I allergy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"used\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Oxatomide\"]], \"start\": [[0]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"diseases mediated by type I allergy\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Oxatomide\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
6453500_2 | Toxic hepatitis induced by disulfiram in a non-alcoholic. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[16]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Toxic hepatitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"disulfiram\"]], \"start\": [[27]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"disulfiram\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}}, \"Subject\": {\"text\": [[\"a non-alcoholic\"]], \"start\": [[41]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
3143551_1 | Accordingly, camptocormia is a dose-dependent side effect of valproate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"effect\"]], \"start\": [[51]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"camptocormia\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[61]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19390192_2 | The uncomplicated long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the leukopenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[146]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"leukopenia\"]], \"start\": [[159]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"long-term use of adequately-dosed AZA and stable non-toxic metabolite levels could not acknowledge TPMT deficiency\"]], \"start\": [[18]], \"entity_id\": [\"T4\"], \"Duration\": {\"text\": [[\"ong-term\"]], \"start\": [[19]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"adequately-dosed\"]], \"start\": [[35]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"AZA\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
17381671_9 | CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[122]], \"entity_id\": [\"T31\"]}, \"Subject\": {\"text\": [[\"65-year-old patient\"]], \"start\": [[16]], \"entity_id\": [\"T29\"], \"Age\": {\"text\": [[\"65-year-old\"]], \"start\": [[16]], \"entity_id\": [\"T30\"]}}, \"Effect\": {\"text\": [[\"confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome\"]], \"start\": [[132]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram\", \"following initiation of fentanyl\"]], \"start\": [[36, 247]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"fentanyl\"], [\"citalopram\"]], \"start\": [[271], [111]], \"entity_id\": [\"T33\", \"T8\"]}, \"Duration\": {\"text\": [[\"chronically\"]], \"start\": [[36]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[247]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"fentanyl\"], [\"citalopram\"]], \"start\": [[271], [111]], \"entity_id\": [\"T33\", \"T8\"]}}]}}"
}
]
}
] |
3941210_2 | Such a case induced by hypothyroidism complicating long-term therapy with amiodarone in a 45 year old woman with pre-excitation is presented. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complicating\"]], \"start\": [[38]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"a 45 year old woman with pre-excitation\"]], \"start\": [[88]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"45 year old\"]], \"start\": [[90]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[102]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hypothyroidism\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"long-term therapy with amiodarone\"]], \"start\": [[51]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[74]], \"entity_id\": [\"T10\"]}, \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"pre-excitation\"]], \"start\": [[113]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
2935070_4 | The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of ampicillin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[139]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ampicillin\"]], \"start\": [[171]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"ampicillin\"]], \"start\": [[171]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"rapid onset of renal failure, presence of eosinophilia, skin rash, and characteristic renal biopsy\"]], \"start\": [[31]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16008658_1 | 46-year-old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta-1b subcutaneously for multiple sclerosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"46-year-old woman\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"46-year-old\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"painful ulcers over her lower abdomen in the form of reticulate erythema\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"injecting interferon beta-1b subcutaneously\"]], \"start\": [[107]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"interferon beta-1b\"]], \"start\": [[117]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"injecting\"]], \"start\": [[107]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"multiple sclerosis\"]], \"start\": [[155]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
10203437_1 | Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Lupus-like syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"5-aminosalicylic acid\"]], \"start\": [[30]], \"entity_id\": [\"T8\"], \"Disorder\": {\"text\": [[\"inflammatory bowel disease\"]], \"start\": [[69]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"5-aminosalicylic acid\"]], \"start\": [[30]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"patients with inflammatory bowel disease\"]], \"start\": [[55]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
566977_1 | Fatal acute tubular necrosis occurred in 1 patient in whom intravesical formalin was used to control massive persistent hemorrhage from radiation cystitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurred\"]], \"start\": [[29]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"acute tubular necrosis\"]], \"start\": [[6]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"1 patient\"]], \"start\": [[41]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"1\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"intravesical formalin\"]], \"start\": [[59]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"massive persistent hemorrhage from radiation cystitis\"]], \"start\": [[101]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intravesical\"]], \"start\": [[59]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"formalin\"]], \"start\": [[72]], \"entity_id\": [\"T10\"]}}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
9302445_3 | The hypercalcemia responded to discontinuation of rhGH and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"responded\"]], \"start\": [[18]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"discontinuation of rhGH and a single dose of intravenous pamidronate disodium\"]], \"start\": [[31]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"hypercalcemia\"]], \"start\": [[4]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"rhGH\"], [\"pamidronate disodium\"]], \"start\": [[50], [88]], \"entity_id\": [\"T7\", \"T9\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[76]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"has not recurred in 8 months of follow-up\"]], \"start\": [[113]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
834512_2 | The administration of "sweet spirits of nitre" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"followed\"]], \"start\": [[101]], \"entity_id\": [\"T13\"]}, \"Treatment\": {\"text\": [[\"\\\"sweet spirits of nitre\\\" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol)\"]], \"start\": [[22]], \"entity_id\": [\"T16\"], \"Drug\": {\"text\": [[\"sweet spirits of nitre\"]], \"start\": [[23]], \"entity_id\": [\"T19\"]}}, \"Effect\": {\"text\": [[\"acute methemoglobinemia and severe anoxic metabolic acidosis\"]], \"start\": [[113]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"infant twins\"]], \"start\": [[177]], \"entity_id\": [\"T15\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[177]], \"entity_id\": [\"T17\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"reversed\"]], \"start\": [[221]], \"entity_id\": [\"T22\"]}, \"Subject\": {\"text\": [[\"infant twins\"]], \"start\": [[177]], \"entity_id\": [\"T15\"], \"Age\": {\"text\": [[\"infant\"]], \"start\": [[177]], \"entity_id\": [\"T17\"]}}, \"Treatment\": {\"text\": [[\"Methylene blue\"]], \"start\": [[191]], \"entity_id\": [\"T20\"], \"Disorder\": {\"text\": [[\"methemoglobinemia\"]], \"start\": [[230]], \"entity_id\": [\"T23\"]}, \"Drug\": {\"text\": [[\"Methylene blue\"]], \"start\": [[191]], \"entity_id\": [\"T21\"]}}}"
},
{
"event_id": "E3",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"died\"]], \"start\": [[270]], \"entity_id\": [\"T26\"]}, \"Treatment\": {\"text\": [[\"\\\"sweet spirits of nitre\\\" (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol)\"]], \"start\": [[22]], \"entity_id\": [\"T16\"], \"Drug\": {\"text\": [[\"sweet spirits of nitre\"]], \"start\": [[23]], \"entity_id\": [\"T19\"]}}, \"Subject\": {\"text\": [[\"one twin\"]], \"start\": [[261]], \"entity_id\": [\"T24\"]}, \"Effect\": {\"text\": [[\"died from the consequences of hypoxemia\"]], \"start\": [[270]], \"entity_id\": [\"T25\"]}, \"Severity\": {\"text\": [[\"died\"]], \"start\": [[270]], \"entity_id\": [\"T27\"], \"value\": \"High\"}}"
}
]
}
] |
12196666_1 | The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid-induced adverse outcome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"susceptibility\"]], \"start\": [[115]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"valproic acid-induced\"]], \"start\": [[133]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"valproic acid\"]], \"start\": [[133]], \"entity_id\": [\"T8\"]}}, \"Subject\": {\"text\": [[\"three families\", \"all the siblings\"]], \"start\": [[21, 69]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"FVS\"]], \"start\": [[62]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17536204_6 | We hypothesize that capecitabine-induced headache is vascular in nature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"capecitabine\"]], \"start\": [[20]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"capecitabine\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"headache\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12792223_2 | A lupus-like syndrome associated with infliximab therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"infliximab\"]], \"start\": [[38]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"infliximab\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"A lupus-like syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
2669373_1 | A case report of a patient with probable cisplatin and bleomycin-induced TMA is presented. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a patient with probable cisplatin\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"bleomycin\"]], \"start\": [[55]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[55]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"probable cisplatin\"]], \"start\": [[32]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"TMA\"]], \"start\": [[73]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
11250985_3 | In some cases this seems to happen because spironolactone causes diarrhoea. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"causes\"]], \"start\": [[58]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"spironolactone\"]], \"start\": [[43]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"spironolactone\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"diarrhoea\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"seems\"]], \"start\": [[19]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
11737689_4 | Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"observed\"]], \"start\": [[39]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"two children\"]], \"start\": [[51]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[51]], \"entity_id\": [\"T12\"]}, \"Age\": {\"text\": [[\"children\"]], \"start\": [[55]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"granulocyte colony-stimulating factor (G-CSF)\"]], \"start\": [[74]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"granulocyte colony-stimulating factor\"]], \"start\": [[74]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"idiopathic neutropenia\"]], \"start\": [[137]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"Painful neutrophilic skin lesions\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
10458196_3 | Apparent central nervous system depression in infants after the use of topical brimonidine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Apparent central nervous system depression\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"infants\"]], \"start\": [[46]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"infants\"]], \"start\": [[46]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"topical brimonidine\"]], \"start\": [[71]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"brimonidine\"]], \"start\": [[79]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"topical\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16284443_4 | To our knowledge, this is the first report of insulin-induced lipohypertrophy with detailed histological examinations. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[54]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"insulin\"]], \"start\": [[46]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"insulin\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"lipohypertrophy\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
19540093_4 | Tigecycline-induced acute pancreatitis: case report and literature review. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Tigecycline\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Tigecycline\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
11850606_3 | Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication of\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"interferon alpha treatment\"]], \"start\": [[39]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Polymyositis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
4038510_3 | Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"protects\"]], \"start\": [[62]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Sodium thiosulfate is a neutralizing agent for cisplatin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"cisplatin\"], [\"Sodium thiosulfate\"]], \"start\": [[47], [0]], \"entity_id\": [\"T10\", \"T11\"]}, \"Disorder\": {\"text\": [[\"renal damage\"]], \"start\": [[79]], \"entity_id\": [\"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"neutralizing agent\"]], \"start\": [[24]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"Sodium thiosulfate\"], [\"cisplatin\"]], \"start\": [[0], [47]], \"entity_id\": [\"T11\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"protects against renal damage\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
19363904_1 | Anaphylactic reaction to bacitracin ointment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reaction\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"bacitracin ointment\"]], \"start\": [[25]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bacitracin\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Anaphylactic\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7679525_1 | Severe bleomycin lung toxicity: reversal with high dose corticosteroids. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[22]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"bleomycin\"]], \"start\": [[7]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"bleomycin\"]], \"start\": [[7]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Severe bleomycin lung toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Severity\": {\"text\": [[\"Severe\"]], \"start\": [[0]], \"entity_id\": [\"T9\"], \"value\": \"Medium\"}}"
}
]
}
] |
11918514_1 | CONCLUSIONS: Although mirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing SS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"bearing\"]], \"start\": [[113]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"SS\"]], \"start\": [[121]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"frail, elderly patients with underlying chronic conditions\"]], \"start\": [[174]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[181]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"underlying chronic conditions\"]], \"start\": [[203]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"mirtazapine\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"mirtazapine\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
536461_1 | Five cases of clindamycin-associated pseudomembranous colitis in leukaemic patients are reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[26]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"clindamycin\"]], \"start\": [[14]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"clindamycin\"]], \"start\": [[14]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"pseudomembranous colitis\"]], \"start\": [[37]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"leukaemic patients\"]], \"start\": [[65]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"leukaemic\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
19707032_6 | Three days after receiving intravitreal injection of bevacizumab (1.25 mg in 0.1 ml), he developed acute vision loss and change of consciousness. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[89]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"intravitreal injection of bevacizumab (1.25 mg in 0.1 ml),\"]], \"start\": [[27]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"intravitreal injection\"]], \"start\": [[27]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"bevacizumab\"]], \"start\": [[53]], \"entity_id\": [\"T11\"]}, \"Dosage\": {\"text\": [[\"1.25 mg in 0.1 ml\"]], \"start\": [[66]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"acute vision loss and change of consciousness\"]], \"start\": [[99]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"he\"]], \"start\": [[86]], \"entity_id\": [\"T8\"], \"Gender\": {\"text\": [[\"he\"]], \"start\": [[86]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
23868369_7 | The proposed cause of the nausea and anorexia was digoxin toxicity secondary to a drug-drug interaction with ciprofloxacin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"secondary\"]], \"start\": [[67]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"nausea and anorexia was digoxin toxicity\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[109]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"digoxin\"]], \"start\": [[109], [50]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[92]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"digoxin\"], [\"ciprofloxacin\"]], \"start\": [[50], [109]], \"entity_id\": [\"T11\", \"T10\"]}}]}, \"Speculated\": {\"text\": [[\"proposed cause\"]], \"start\": [[4]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
8222875_1 | Mitomycin C (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome (HUS). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[64]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Mitomycin C (MMC)\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Mitomycin C\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"the hemolytic-uremic syndrome (HUS)\"]], \"start\": [[80]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
10904571_3 | Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[114]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"colchicine\"]], \"start\": [[103]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"colchicine\"]], \"start\": [[103]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"variation in muscle fiber size and few vacuolated fibers\", \"myopathy\"]], \"start\": [[23, 122]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
1467295_1 | We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and mitoxantrone. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"provoked\"]], \"start\": [[68]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cytarabine and mitoxantrone\"]], \"start\": [[119]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cytarabine\"], [\"mitoxantrone\"]], \"start\": [[119], [134]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[130]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"cytarabine\"], [\"mitoxantrone\"]], \"start\": [[119], [134]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"NEH\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
22791547_4 | Orofacial dyskinesia appeared 5 hours after methylphenidate administration, persisted for 10 hours, and had completely resolved within 2 days. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"appeared\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Orofacial dyskinesia\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"5 hours after methylphenidate\"]], \"start\": [[30]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methylphenidate\"]], \"start\": [[44]], \"entity_id\": [\"T7\"]}, \"Time_elapsed\": {\"text\": [[\"5 hours after\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19789372_7 | Present results suggested that coadministration of mexiletine increased blood tizanidine concentrations and enhanced tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"enhanced\"]], \"start\": [[108]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"tizanidine pharmacodynamics in terms of reduction in blood pressure and adverse symptoms\"]], \"start\": [[117]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"coadministration of mexiletine increased blood tizanidine concentrations\"]], \"start\": [[31]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"mexiletine\"], [\"tizanidine\"]], \"start\": [[51], [78]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"increased\"]], \"start\": [[62]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"mexiletine\"], [\"tizanidine\"]], \"start\": [[51], [78]], \"entity_id\": [\"T13\", \"T14\"]}}]}, \"Speculated\": {\"text\": [[\"suggested\"]], \"start\": [[16]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
7272895_3 | Bilateral acoustic (VIII) nerve palsy in this patient was most likely a manifestation of vincristine neurotoxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"most likely\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Bilateral acoustic (VIII) nerve palsy\", \"neurotoxicity\"]], \"start\": [[0, 101]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"this patient\"]], \"start\": [[41]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"vincristine\"]], \"start\": [[89]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"vincristine\"]], \"start\": [[89]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
633424_1 | Acute leukopenia associated with silver sulfadiazine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute leukopenia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"silver sulfadiazine\"]], \"start\": [[33]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"silver sulfadiazine\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
12135176_3 | We describe two cases of PSVT that changed to non-sustained polymorphic ventricular tachycardia after administration of verapamil. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"changed\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"non-sustained polymorphic ventricular tachycardia\"]], \"start\": [[46]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"administration of verapamil.\"]], \"start\": [[102]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"verapamil\"]], \"start\": [[120]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"PSVT\"]], \"start\": [[25]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"two cases of PSVT\"]], \"start\": [[12]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
8301877_4 | We described the occurrence of L-dopa-induced myoclonus and seizures in a case of parkinsonism with its SEPs findings. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[38]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"L-dopa\"]], \"start\": [[31]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"L-dopa\"]], \"start\": [[31]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"parkinsonism\"]], \"start\": [[82]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"myoclonus and seizures\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"case of parkinsonism\"]], \"start\": [[74]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
12187348_8 | Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause of\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"bucillamine\"]], \"start\": [[17]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"bucillamine\"], [\"D-penicillamine\"]], \"start\": [[17], [123]], \"entity_id\": [\"T11\", \"T12\"]}}, \"Effect\": {\"text\": [[\"giant hypertrophy\"]], \"start\": [[65]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
11886466_5 | We speculate that platelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"contributed\"]], \"start\": [[65]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"pFVIII\"]], \"start\": [[49]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"pFVIII\"]], \"start\": [[49]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"cardiovascular\"]], \"start\": [[174]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"thrombosis\"]], \"start\": [[80]], \"entity_id\": [\"T12\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[56]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
11181395_1 | Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[66]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Restoration of vancomycin susceptibility in Enterococcus faecalis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"antiresistance determinant gene transfer\"]], \"start\": [[69]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"vancomycin\"]], \"start\": [[15]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
9824032_1 | Dental and gingival pain as side effects of niacin therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side effects\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Dental and gingival pain\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"niacin\"]], \"start\": [[44]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"niacin\"]], \"start\": [[44]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
12590235_5 | We describe a case of significant elevation of serum transaminases in a patient treated with 6-TG for a flare of Crohn's disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"elevation\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"significant elevation of serum transaminases\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[70]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"6-TG\"]], \"start\": [[93]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[113]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"6-TG\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
6236730_1 | A patient developed transient, acute myopia while on isotretinoin (Accutane) therapy for acne. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[10]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"acne\", \"A patient\"]], \"start\": [[89, 0]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"transient, acute myopia\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"isotretinoin (Accutane)\"]], \"start\": [[53]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"acne\"]], \"start\": [[89]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"isotretinoin\"]], \"start\": [[53]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
18094347_2 | CONCLUSIONS: The pathogenesis of methotrexate-induced papular eruption in collagen vascular diseases may suggest cutaneous small-vessel vasculitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[46]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"papular eruption\"]], \"start\": [[54]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[33]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"collagen vascular diseases\"]], \"start\": [[74]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[33]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[101]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
1536494_1 | Aminophylline hypersensitivity apparently due to ethylenediamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Aminophylline hypersensitivity\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ethylenediamine\"]], \"start\": [[49]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ethylenediamine\"]], \"start\": [[49]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"apparently\"]], \"start\": [[31]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
3804181_3 | The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"demonstrated\"]], \"start\": [[232]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"antithyroid therapy with 20 mg methimazole daily\"]], \"start\": [[277]], \"entity_id\": [\"T12\"], \"Time_elapsed\": {\"text\": [[\"20 days after\"]], \"start\": [[245]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"methimazole\"]], \"start\": [[308]], \"entity_id\": [\"T18\"]}, \"Dosage\": {\"text\": [[\"20 mg\"]], \"start\": [[302]], \"entity_id\": [\"T19\"]}, \"Freq\": {\"text\": [[\"daily\"]], \"start\": [[320]], \"entity_id\": [\"T20\"]}}, \"Subject\": {\"text\": [[\"this 58-year-old female\"]], \"start\": [[30]], \"entity_id\": [\"T13\"], \"Age\": {\"text\": [[\"58-year-old\"]], \"start\": [[35]], \"entity_id\": [\"T15\"]}, \"Gender\": {\"text\": [[\"female\"]], \"start\": [[47]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis\"]], \"start\": [[90]], \"entity_id\": [\"T14\"]}}"
}
]
}
] |
19892516_4 | In one patient the vasculitis resolved after termination of the ciprofloxacin therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[126]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[112]], \"entity_id\": [\"T13\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[112]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation\"]], \"start\": [[134]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[100]], \"entity_id\": [\"T11\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[179]], \"entity_id\": [\"T24\"], \"value\": \"Medium\"}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolved\"]], \"start\": [[30]], \"entity_id\": [\"T20\"]}, \"Subject\": {\"text\": [[\"one patient the vasculitis\"]], \"start\": [[3]], \"entity_id\": [\"T17\"], \"Population\": {\"text\": [[\"one\"]], \"start\": [[3]], \"entity_id\": [\"T18\"]}}, \"Treatment\": {\"text\": [[\"termination of the ciprofloxacin therapy\"]], \"start\": [[45]], \"entity_id\": [\"T21\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"]], \"start\": [[64]], \"entity_id\": [\"T22\"]}, \"Disorder\": {\"text\": [[\"vasculitis\"]], \"start\": [[19]], \"entity_id\": [\"T23\"]}}}"
}
]
}
] |
9719245_1 | Excluding other causes, Pentasa-associated pancytopenia was considered. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Pentasa\"]], \"start\": [[24]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Pentasa\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"pancytopenia\"]], \"start\": [[43]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
15013892_3 | RESULTS: A patient developed a bilaterally symmetric bull's-eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"A patient\"], [\"bilaterally symmetric bull's-eye maculopathy\"]], \"start\": [[9], [31]], \"entity_id\": [\"T3\", \"T4\"]}, \"Treatment\": {\"text\": [[\"45 years after taking quinacrine for 18 months\"]], \"start\": [[76]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"45 years after\"], [\"18 months\"]], \"start\": [[76], [113]], \"entity_id\": [\"T8\", \"T10\"]}, \"Drug\": {\"text\": [[\"quinacrine\"]], \"start\": [[98]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"malaria\"]], \"start\": [[146]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
23868369_1 | Possible digoxin toxicity associated with concomitant ciprofloxacin therapy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[26]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"digoxin toxicity\"]], \"start\": [[9]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin\", \"digoxin\"]], \"start\": [[54, 9]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"digoxin\"]], \"start\": [[54], [9]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concomitant\"]], \"start\": [[42]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"digoxin\"]], \"start\": [[54], [9]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Speculated\": {\"text\": [[\"Possible\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"value\": true}}"
}
]
}
] |
8313300_9 | The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"improved\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"within 72 hours of the withdrawal of lithium\"]], \"start\": [[39]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"exophthalmos\"]], \"start\": [[4]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[76]], \"entity_id\": [\"T6\"]}, \"Time_elapsed\": {\"text\": [[\"within 72 hours\"]], \"start\": [[39]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8255797_3 | We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[35]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"two cases of\", \"cardiac patients with trisomy 21\"]], \"start\": [[10, 62]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"cardiac\"], [\"trisomy 21\"]], \"start\": [[62], [84]], \"entity_id\": [\"T8\", \"T1\"]}}, \"Effect\": {\"text\": [[\"neutropenia\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"captopril use\"]], \"start\": [[45]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[45]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
1433432_2 | We report a case of hyponatremia associated with a grand mal seizure in a 28 month-old child after intra-nasal desmopressin administration for high fluid intake with nocturnal enuresis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[93]], \"entity_id\": [\"T12\"]}, \"Effect\": {\"text\": [[\"hyponatremia associated with a grand mal seizure\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a 28 month-old child\"]], \"start\": [[72]], \"entity_id\": [\"T9\"], \"Age\": {\"text\": [[\"28 month-old child\"]], \"start\": [[74]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"intra-nasal desmopressin administration\"]], \"start\": [[99]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"high fluid intake with nocturnal enuresis\"]], \"start\": [[143]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"desmopressin\"]], \"start\": [[111]], \"entity_id\": [\"T15\"]}, \"Route\": {\"text\": [[\"intra-nasal\"]], \"start\": [[99]], \"entity_id\": [\"T16\"]}}}"
}
]
}
] |
9719245_2 | He developed fever, nausea, diarrhea, and malaise and stopped taking on the third day after commencing Pentasa. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[3]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"Pentasa\"]], \"start\": [[103]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"Pentasa\"]], \"start\": [[103]], \"entity_id\": [\"T14\"]}, \"Time_elapsed\": {\"text\": [[\"third day\"]], \"start\": [[76]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"fever, nausea, diarrhea, and malaise\"]], \"start\": [[13]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"Gender\": {\"text\": [[\"He\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
15752306_1 | Livedo reticularis associated with interferon alpha therapy in two melanoma patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[19]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"two melanoma patients\"]], \"start\": [[63]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[63]], \"entity_id\": [\"T13\"]}}, \"Treatment\": {\"text\": [[\"interferon alpha therapy\"]], \"start\": [[35]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"melanoma\"]], \"start\": [[67]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[35]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"Livedo reticularis\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
10656221_4 | A 60-year-old woman with diabetes mellitus (type 2) developed an acute icteric hepatitis-like illness 6 weeks after the initiation of gliclazide therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[52]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"A 60-year-old woman with diabetes mellitus (type 2)\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"60-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[14]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"6 weeks after the initiation of gliclazide therapy\"]], \"start\": [[102]], \"entity_id\": [\"T7\"], \"Time_elapsed\": {\"text\": [[\"6 weeks\"]], \"start\": [[102]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"gliclazide\"]], \"start\": [[134]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"diabetes mellitus (type 2)\"]], \"start\": [[25]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"an acute icteric hepatitis-like illness\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
1348483_3 | Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"bromocriptine\", \"cabergoline\"]], \"start\": [[68, 5]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cabergoline\"], [\"bromocriptine\"]], \"start\": [[5], [68]], \"entity_id\": [\"T10\", \"T11\"]}}, \"Effect\": {\"text\": [[\"pleuropulmonary abnormalities\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[17]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
7067510_1 | Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation cannot be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient coronary vasoconstriction induced by the dopamine infusion. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[330]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"transient coronary vasoconstriction\"]], \"start\": [[294]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"dopamine\"]], \"start\": [[345]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"dopamine\"]], \"start\": [[345]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7594371_1 | Acute sensorineural hearing loss following intravenous ketoralac administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[33]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Acute sensorineural hearing loss\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"intravenous ketoralac\"]], \"start\": [[43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ketoralac\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16484748_3 | Trimethoprim-sulfamethoxazole-induced hypersensitivity syndrome associated with reactivation of human herpesvirus-6. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Trimethoprim-sulfamethoxazole\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Trimethoprim-sulfamethoxazole\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome associated with reactivation of human herpesvirus-6\"]], \"start\": [[38]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
1775411_1 | A patient is described who developed a rapid onset of pulmonary fibrosis following treatment with a new non-steroidal anti-inflammatory drug, nabumetone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[27]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"pulmonary fibrosis\"]], \"start\": [[54]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"nabumetone\"]], \"start\": [[142]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"nabumetone\"]], \"start\": [[142]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
11675845_2 | To report a case of increased international normalized ratio (INR) in a geriatric patient receiving warfarin and ropinirole. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"case\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"warfarin and ropinirole\"]], \"start\": [[100]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"warfarin\"], [\"ropinirole\"]], \"start\": [[100], [113]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[109]], \"entity_id\": [\"T15\"]}, \"Drug\": {\"text\": [[\"ropinirole\"], [\"warfarin\"]], \"start\": [[113], [100]], \"entity_id\": [\"T14\", \"T13\"]}}]}, \"Subject\": {\"text\": [[\"a geriatric patient\"]], \"start\": [[70]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"geriatric\"]], \"start\": [[72]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"increased international normalized ratio (INR)\"]], \"start\": [[20]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.